Literature DB >> 16423632

Soluble P-selectin and CD40L levels in subjects with prediabetes, diabetes mellitus, and metabolic syndrome--the Chennai Urban Rural Epidemiology Study.

Kuppan Gokulakrishnan1, Raj Deepa, Viswanathan Mohan, Myron D Gross.   

Abstract

The aim of the study was to determine whether the levels of soluble P-selectin (sP-selectin) and soluble CD40L (sCD40L) are elevated in Asian Indian subjects with impaired glucose tolerance (IGT), diabetes, and metabolic syndrome (MS). Study subjects were recruited from the Chennai Urban Rural Epidemiology Study (CURES), an ongoing population-based study on a representative population of Chennai city in southern India, and were grouped as follows: group 1, normal glucose tolerance (NGT) (n = 60); group 2, IGT (n = 60); and group 3, type 2 diabetes mellitus (n = 60). Normal glucose tolerance, IGT, and diabetes were defined using World Health Organization consulting group criteria. The inclusion criteria were nonsmokers; normal resting 12-lead electrocardiogram; absence of angina, myocardial infarction, or history of any known vascular, infectious, or inflammatory diseases; and subjects not on statins or aspirin. Insulin resistance was calculated using the homeostasis assessment model using the formula: fasting insulin (microIU/mL) x fasting glucose (mmol/L)/22.5. Soluble P-selectin and sCD40L were estimated by enzyme-linked immunosorbent assay. Metabolic syndrome was defined using Adult Treatment Panel III guidelines. Subjects with diabetes and IGT were older (diabetes: 53 +/- 9 years, P < .01; IGT: 51 +/- 10 years, P < .05) compared with the NGT group (48 +/- 10 years). Subjects with diabetes and IGT had higher levels of sP-selectin (diabetes: 162 +/- 79 ng/mL, P < .001; IGT: 102 +/- 37 ng/mL, P < .001) compared with the NGT group (55 +/- 48 ng/mL). Soluble CD40L levels were also higher in those with diabetes and IGT (diabetes: 3.2 +/- 2.0 ng/mL, P < .001; IGT: 2.0 +/- 1.3 ng/mL, P < .001) compared with the NGT group (1.1 +/- 0.9 ng/mL). Subjects with MS had significantly higher levels of sP-selectin (with MS, 118 +/- 76 ng/mL; without MS, 95 +/- 66 ng/mL; P = .028) and sCD40L (with MS, 2.4 +/- 1.8 ng/mL; without MS, 1.9 +/- 1.5 ng/mL; P = .036) compared with subjects without MS. Among subjects with NGT and IGT, the mean levels of sP-selectin (tertile I, 65.0 ng/mL; tertile II, 80.0 ng/mL; tertile III, 91.0 ng/mL) and sCD40L levels (tertile I, 1.2 ng/mL; tertile II, 1.7 ng/mL; tertile III, 1.8 ng/mL) increased with increase in tertiles of homeostasis assessment model-insulin resistance, and the difference reached statistical significance in the last tertile compared with the first tertile (P < .05). This study demonstrates that increased levels of sP-selectin and sCD40L are seen in Asian Indian subjects with IGT, type 2 diabetes mellitus, MS, and insulin resistance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16423632     DOI: 10.1016/j.metabol.2005.08.019

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  26 in total

1.  Suboptimal inhibition of platelet cyclooxygenase-1 by aspirin in metabolic syndrome.

Authors:  James P Smith; Elias V Haddad; Mary B Taylor; Denise Oram; Dana Blakemore; Qingxia Chen; Olivier Boutaud; John A Oates
Journal:  Hypertension       Date:  2012-02-06       Impact factor: 10.190

2.  Soluble CD40 ligand levels in acute pulmonary embolism: a prospective, randomized, controlled study.

Authors:  Zeynettin Kaya; Kurtulus Ozdemir; Mehmet Kayrak; Enes Elvin Gul; Gokhan Altunbas; Cetin Duman; Aysel Kiyici
Journal:  Heart Vessels       Date:  2011-04-14       Impact factor: 2.037

Review 3.  CD40/CD40L system and vascular disease.

Authors:  F Santilli; S Basili; P Ferroni; G Davì
Journal:  Intern Emerg Med       Date:  2007-11-28       Impact factor: 3.397

4.  Enhanced P-selectin expression on platelet-a marker of platelet activation, in young patients with angiographically proven coronary artery disease.

Authors:  Reema George; Anugya Bhatt; Jayakumari Narayani; Jissa Vinoda Thulaseedharan; Harikrishnan Sivadasanpillai; Jaganmohan A Tharakan
Journal:  Mol Cell Biochem       Date:  2016-07-12       Impact factor: 3.396

5.  Modification of platelet proteins by malondialdehyde: prevention by dicarbonyl scavengers.

Authors:  Irene Zagol-Ikapite; Iberia R Sosa; Denise Oram; Audra Judd; Kalyani Amarnath; Venkataraman Amarnath; Donald Stec; John A Oates; Olivier Boutaud
Journal:  J Lipid Res       Date:  2015-09-16       Impact factor: 5.922

6.  The markers of inflammation and endothelial dysfunction in correlation with glycated haemoglobin are present in type 2 diabetes mellitus patients but not in their relatives.

Authors:  José Manuel Gómez; Ramon Vila; Pablo Catalina; Juan Soler; Lina Badimón; Manel Sahún
Journal:  Glycoconj J       Date:  2008-03-18       Impact factor: 2.916

Review 7.  Adipocytokines in atherothrombosis: focus on platelets and vascular smooth muscle cells.

Authors:  Giovanni Anfossi; Isabella Russo; Gabriella Doronzo; Alice Pomero; Mariella Trovati
Journal:  Mediators Inflamm       Date:  2010-06-28       Impact factor: 4.711

8.  Native platelet aggregation and response to aspirin in persons with the metabolic syndrome and its components.

Authors:  Dhananjay Vaidya; Lisa R Yanek; Nauder Faraday; Taryn F Moy; Lewis C Becker; Diane M Becker
Journal:  Metab Syndr Relat Disord       Date:  2009-08       Impact factor: 1.894

9.  Acute suppression of circulating sCD40L during hyperglycemia and euglycemic-hyperinsulinemia in healthy young males.

Authors:  Stacy R Oliver; Rebecca L Flores; Andria M Pontello; Jaime S Rosa; Frank P Zaldivar; Pietro R Galassetti
Journal:  J Investig Med       Date:  2008-10       Impact factor: 2.895

10.  Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome.

Authors:  Long Wang; Jason Rockwood; Danielle Zak; Sridevi Devaraj; Ishwarlal Jialal
Journal:  Metab Syndr Relat Disord       Date:  2008-06       Impact factor: 1.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.